Automate Your Wheel Strategy on GRAL
With Tiblio's Option Bot, you can configure your own wheel strategy including GRAL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GRAL
- Rev/Share 3.8307
- Book/Share 66.0291
- PB 1.1937
- Debt/Equity 0.0269
- CurrentRatio 9.2278
- ROIC -0.1989
- MktCap 2841281527.0
- FreeCF/Share -10.6049
- PFCF -7.6429
- PE -6.2378
- Debt/Assets 0.023
- DivYield 0
- ROE -0.1804
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | GRAL | Canaccord Genuity | -- | Buy | -- | $32 | April 21, 2025 |
| Initiation | GRAL | Guggenheim | -- | Neutral | -- | -- | Oct. 17, 2024 |
News
Grail: A Speculative Buy
Published: September 30, 2025 by: Seeking Alpha
Sentiment: Neutral
Grail, Inc. represents a speculative long-term investment opportunity, conditional on the FDA's approval of its Galleri multi-cancer early detection blood test and its widespread adoption among the general population. Assuming FDA approval, GRAL could reach $100–$250 per share, based on reasonable assumptions regarding its total addressable market and the prevailing competitive landscape. Galleri's robust revenue growth as a predominantly self-paid test over the past three years provides a reasonable margin of safety against the risk of FDA non-approval.
Read More
GRAIL to Present New Galleri® Data From More Than 32,000 Participants Across the PATHFINDER 2, SYMPLIFY and REFLECTION Studies at ESMO Congress 2025 and EDCC
Published: September 23, 2025 by: PRNewsWire
Sentiment: Neutral
First PATHFINDER 2 Results Accepted as a Late-Breaking Presentation at the European Society for Medical Oncology (ESMO) Congress 2025; Results to be Submitted to FDA as Part of the Galleri Premarket Approval Application (PMA) Updated SYMPLIFY and REFLECTION Study Results to be Presented at the Early Detection of Cancer Conference (EDCC) Highlight Galleri Performance in Symptomatic and Veteran Populations, Respectively MENLO PARK, Calif. , Sept. 23, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, will present new data highlighting the Galleri® multi-cancer early detection (MCED) test …
Read More
Sun World International and Pairwise Launch Strategic Partnership to Develop a Holy Grail of Produce – the Pitless Cherry
Published: September 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Joint Venture Combines Advanced Plant Breeding Technology with Global Fruit Expertise to Deliver Consumer-Desired Traits Joint Venture Combines Advanced Plant Breeding Technology with Global Fruit Expertise to Deliver Consumer-Desired Traits
Read More
The Holy Grail of Automation: Now a Robot Can Unload a Truck
Published: June 23, 2025 by: WSJ
Sentiment: Positive
Technology breakthroughs are allowing DHL and other companies to automate the laborious, injury-prone work of loading and unloading.
Read More
Grail Shares Jump on Promising Results for Galleri Study
Published: June 18, 2025 by: Market Watch
Sentiment: Positive
Shares of Grail climbed after the company said the second study of its Galleri multi-cancer early detection test provided even more promising results than the first.
Read More
GRAIL Announces Positive Top-Line Results From The Galleri® PATHFINDER 2 Registrational Study
Published: June 18, 2025 by: PRNewsWire
Sentiment: Neutral
Cancer Detection and Positive Predictive Value Substantially Higher Than the Previously Published PATHFINDER Study MENLO PARK, Calif. , June 18, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced positive top-line performance and safety results from the pre-specified analysis of the first 25,578 participants in GRAIL's registrational PATHFINDER 2 study.
Read More
GRAIL Partners With Actress Kate Walsh for Generation Possible to Raise Awareness of Multi-Cancer Early Detection Testing
Published: February 25, 2025 by: PRNewsWire
Sentiment: Neutral
MENLO PARK, Calif. , Feb. 25, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose mission is to detect cancer early when it can be cured, has partnered with award-winning actress Kate Walsh to launch Generation Possible, an educational initiative to raise awareness of multi-cancer early detection (MCED) testing.
Read More
GRAIL to Present at TD Cowen 45th Annual Health Care Conference
Published: February 21, 2025 by: PRNewsWire
Sentiment: Neutral
MENLO PARK, Calif. , Feb. 21, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the TD Cowen 45th Annual Health Care Conference in Boston on Tuesday, Mar. 4 at 9:10 a.m.
Read More
GRAIL, Inc. (GRAL) Q4 2024 Earnings Call Transcript
Published: February 20, 2025 by: Seeking Alpha
Sentiment: Neutral
GRAIL, Inc. (NASDAQ:GRAL ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Bob Ragusa - Chief Executive Officer and Board Member Aaron Freidin - Chief Financial Officer Joshua Ofman - President Sir Harpal Kumar - President of International Business and BioPharma Conference Call Participants Doug Schenkel - Wolfe Research Operator Good day, ladies and gentlemen, and welcome to the GRAIL Fourth Quarter 2024 Earnings Call. At this time, all participants are in listen-only mode.
Read More
GRAIL Reports Fourth Quarter and Full Year 2024 Financial Results
Published: February 20, 2025 by: PRNewsWire
Sentiment: Neutral
Sold More than 137,000 Galleri® Tests in 2024, Growing U.S. Galleri Revenue 45% Year-Over-Year to $108.6 Million Completed Study Visits for Two Registrational Studies in July to Support Modular PMA Submission for Galleri On Track for Continued Commercial Growth in 2025 with TRICARE Coverage and Recent Announcement of Quest Integration Moderated Cash Burn, Ending 2024 with a Cash Position of $767M, Extending Runway into 2028 MENLO PARK, Calif. , Feb. 20, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for …
Read More
GRAIL to Announce Fourth Quarter 2024 Financial Results
Published: February 12, 2025 by: PRNewsWire
Sentiment: Neutral
MENLO PARK, Calif. , Feb. 12, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the fourth quarter 2024 following the close of market on Thursday, Feb. 20, 2025.
Read More
About GRAIL, Inc. (GRAL)
- IPO Date 2024-06-12
- Website https://grail.com
- Industry Medical - Diagnostics & Research
- CEO Robert P. Ragusa
- Employees 1000